 Paclitaxel
"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Anzatax- Anzatax
- Bull Brand of Paclitaxel
Taxol- Taxol
- Taxol A
- Bristol-Myers Squibb Brand of Paclitaxel
- Bris Taxol
- Bristol-Myers Brand of Paclitaxel
Praxel- Praxel
- Lemery Brand of Paclitaxel
Onxol- Onxol
- Ivax Brand of Paclitaxel
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 4 | 1 | 5 | | 1997 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 1 | 4 | | 2000 | 0 | 6 | 6 | | 2001 | 2 | 1 | 3 | | 2002 | 2 | 3 | 5 | | 2003 | 3 | 1 | 4 | | 2004 | 2 | 2 | 4 | | 2005 | 2 | 2 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 6 | 5 | 11 | | 2008 | 5 | 4 | 9 | | 2009 | 4 | 3 | 7 | | 2010 | 2 | 5 | 7 | | 2011 | 4 | 0 | 4 | | 2012 | 4 | 2 | 6 | | 2013 | 0 | 2 | 2 | | 2014 | 5 | 3 | 8 | | 2015 | 3 | 1 | 4 | | 2016 | 2 | 2 | 4 | | 2017 | 2 | 3 | 5 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Alam A, Kowal J, Broude E, Roninson I, Locher KP. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 2019 02 15; 363(6428):753-756.
-
Monteiro LOF, Fernandes RS, Oda CMR, Lopes SC, Townsend DM, Cardoso VN, Oliveira MC, Leite EA, Rubello D, de Barros ALB. Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study. Biomed Pharmacother. 2018 Jan; 97:489-495.
-
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
-
Drago-Ferrante R, Pentimalli F, Carlisi D, De Blasio A, Saliba C, Baldacchino S, Degaetano J, Debono J, Caruana-Dingli G, Grech G, Scerri C, Tesoriere G, Giordano A, Vento R, Di Fiore R. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget. 2017 Apr 25; 8(17):28939-28958.
-
Monteiro LOF, Fernandes RS, Castro LC, Cardoso VN, Oliveira MC, Townsend DM, Ferretti A, Rubello D, Leite EA, de Barros ALB. Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo. Biomed Pharmacother. 2017 May; 89:146-151.
-
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
-
Jacobi J, García-Barros M, Rao S, Rotolo JA, Thompson C, Mizrachi A, Feldman R, Manova K, Bielawska A, Bielawska J, Fuks Z, Kolesnick R, Haimovitz-Friedman A. Targeting acid sphingomyelinase with anti-angiogenic chemotherapy. Cell Signal. 2017 01; 29:52-61.
-
Rose PG, Java JJ, Morgan MA, Alvarez-Secord A, Kesterson JP, Stehman FB, Warshal DP, Creasman WT, Hanjani P, Morris RT, Copeland LJ. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
-
Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24(6):1150-1158.
-
Wooster M, Dansey K, Shames M. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery. Vasc Endovascular Surg. 2016 Feb; 50(2):80-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|